ArriVent BioPharma, Inc. — All Filings
136 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
All
10-K
10-Q
3
4
424B4
424B5
8-A12B
8-K
8-K/A
ARS
CERT
CORRESP
D
D/A
DEF 14A
DEFA14A
DRS
DRS/A
DRSLTR
EFFECT
S-1
S-1/A
S-1MEF
S-3ASR
S-8
SC 13D
SC 13G
SCHEDULE 13D/A
SCHEDULE 13G
SCHEDULE 13G/A
SEC STAFF LETTER
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| 8-K | 8-K | 0001558370-25-002002 | Mar 3, 2025 | — |
| 10-K | 10-K | 0001558370-25-001999 | Mar 3, 2025 | Dec 31, 2024 |
| S-8 | FORM S-8 | 0001104659-25-019484 | Mar 3, 2025 | — |
| 4 | OWNERSHIP DOCUMENT | 0001104659-25-014160 | Feb 14, 2025 | Feb 3, 2025 |
| SCHEDULE 13G | — | 0000950170-25-021707 | Feb 14, 2025 | — |
| 4 | OWNERSHIP DOCUMENT | 0001104659-25-014175 | Feb 14, 2025 | Feb 3, 2025 |
| 4 | OWNERSHIP DOCUMENT | 0001104659-25-014172 | Feb 14, 2025 | Feb 3, 2025 |
| 4 | OWNERSHIP DOCUMENT | 0001104659-25-014170 | Feb 14, 2025 | Feb 3, 2025 |
| 4 | OWNERSHIP DOCUMENT | 0001104659-25-014164 | Feb 14, 2025 | Feb 3, 2025 |
| S-3ASR | S-3ASR | 0001104659-25-008356 | Feb 3, 2025 | — |
| 8-K | FORM 8-K | 0001104659-25-004967 | Jan 22, 2025 | Jan 21, 2025 |
| SC 13G | — | 0000919574-24-007004 | Dec 4, 2024 | — |
| 10-Q | 10-Q | 0001558370-24-015624 | Nov 14, 2024 | Sep 30, 2024 |
| 8-K | 8-K | 0001558370-24-015622 | Nov 14, 2024 | — |
| SC 13G | ARRIVENT BIOPHARMA, INC. | 0000902664-24-006621 | Nov 14, 2024 | — |
| SC 13G | SC 13G | 0001104659-24-116708 | Nov 12, 2024 | — |
| SC 13G | — | 0000315066-24-002662 | Nov 12, 2024 | — |
| SC 13G | — | 0002012383-24-003521 | Nov 8, 2024 | — |
| SC 13G | — | 0002012383-24-002199 | Oct 24, 2024 | — |
| SC 13G | — | 0001214659-24-017477 | Oct 11, 2024 | — |
| 4 | OWNERSHIP DOCUMENT | 0001104659-24-102146 | Sep 23, 2024 | Sep 19, 2024 |
| 8-K | FORM 8-K | 0001104659-24-098059 | Sep 9, 2024 | — |
| 10-Q | 10-Q | 0001558370-24-012236 | Aug 14, 2024 | Jun 30, 2024 |
| 8-K | 8-K | 0001558370-24-012223 | Aug 14, 2024 | — |
| 8-K/A | 8-K/A | 0001104659-24-078587 | Jul 9, 2024 | May 16, 2024 |
| 8-K/A | FORM 8-K/A | 0001104659-24-078585 | Jul 9, 2024 | Apr 20, 2024 |
| 8-K | FORM 8-K | 0001104659-24-068503 | Jun 5, 2024 | Jun 4, 2024 |
| 3 | OWNERSHIP DOCUMENT | 0001104659-24-063516 | May 20, 2024 | May 16, 2024 |
| 4 | OWNERSHIP DOCUMENT | 0001104659-24-063518 | May 20, 2024 | May 16, 2024 |
| 8-K | FORM 8-K | 0001104659-24-062528 | May 16, 2024 | — |
| 10-Q | 10-Q | 0001558370-24-007197 | May 8, 2024 | Mar 31, 2024 |
| 8-K | 8-K | 0001558370-24-007196 | May 8, 2024 | — |
| 3 | OWNERSHIP DOCUMENT | 0001104659-24-050572 | Apr 23, 2024 | Apr 20, 2024 |
| 4 | OWNERSHIP DOCUMENT | 0001104659-24-050577 | Apr 23, 2024 | Apr 22, 2024 |
| 8-K | FORM 8-K | 0001104659-24-049988 | Apr 22, 2024 | Apr 20, 2024 |
| 10-K | 10-K | 0001558370-24-004280 | Mar 28, 2024 | Dec 31, 2023 |
| 8-K | FORM 8-K | 0001104659-24-040532 | Mar 28, 2024 | — |
| SC 13G | SCHEDULE 13G | 0001213900-24-013438 | Feb 13, 2024 | — |
| SC 13D | SCHEDULE 13D | 0000947871-24-000091 | Feb 5, 2024 | — |
| S-8 | FORM S-8 | 0001104659-24-010025 | Feb 2, 2024 | — |
| 4 | — | 0000902664-24-000903 | Feb 1, 2024 | Jan 30, 2024 |
| 4 | OWNERSHIP DOCUMENT | 0001104659-24-008797 | Jan 31, 2024 | Jan 30, 2024 |
| 4 | OWNERSHIP DOCUMENT | 0001104659-24-008796 | Jan 31, 2024 | Jan 30, 2024 |
| 4 | OWNERSHIP DOCUMENT | 0001104659-24-008799 | Jan 31, 2024 | Jan 30, 2024 |
| 8-K | FORM 8-K | 0001104659-24-008228 | Jan 30, 2024 | — |
| 4 | OWNERSHIP DOCUMENT | 0001104659-24-007732 | Jan 29, 2024 | Jan 25, 2024 |
| 4 | OWNERSHIP DOCUMENT | 0001104659-24-007733 | Jan 29, 2024 | Jan 25, 2024 |
| 424B4 | 424B4 | 0001104659-24-007261 | Jan 26, 2024 | — |
| SEC STAFF LETTER | — | 9999999997-24-000221 | Jan 26, 2024 | — |
| 3 | OWNERSHIP DOCUMENT | 0001104659-24-006838 | Jan 25, 2024 | — |